

Frontiers in Clinical Drug Research
Anti Allergy Agents

Editor:
Atta-ur-Rahman, *FRS*

Bentham Books

Frontiers in Clinical Drug Research – Anti Allergy Agents

(Volume 5)

Edited by

Atta-ur-Rahman, *FRS*

*Kings College,
University of Cambridge,
Cambridge,
UK*

Highly Influential Publications in the Field of

Volume # 5

Editor: Prof. Atta-ur-Rahman, FRS

ISSN (Online): 2214-6938

ISSN (Print): 2452-3194

ISBN (Online): 978-981-5040-61-6

ISBN (Print): 978-981-5040-62-3

ISBN (Revised): 978-981-5040-63-0

©2022, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	ii
CHAPTER 1 RESISTIN: AN IRRESISTIBLE THERAPEUTIC TARGET FOR INFLAMMATORY DISEASES, ALLERGY-RELATED DISORDERS, AND CANCER	1
<i>Erva Ozkan and Filiz Bakar Ates</i>	
INTRODUCTION	2
RESISTIN	2
Structure and Function	2
THE ROLE OF RESISTIN IN DISEASES	4
Inflammatory Diseases	4
<i>Obesity</i>	4
<i>Insulin Resistance and Type-2-Diabetes</i>	5
<i>Atherosclerosis</i>	9
<i>Rheumatoid Arthritis and Osteoarthritis</i>	11
<i>Other Inflammatory Diseases</i>	15
Allergic Disorders	16
Resistin at the Crossroad of Inflammation and Cancer	18
<i>The roles of Resistin in Cancer</i>	20
<i>Invasion and Migration</i>	25
<i>Chemoresistance</i>	27
CONCLUSION	29
CONSENT FOR PUBLICATION	29
CONFLICTS OF INTEREST	29
ACKNOWLEDGEMENTS	29
REFERENCES	29
CHAPTER 2 ASTHMA IN ADULTS: EVALUATION, PREVALENCE, AND ITS CLINICAL MANAGEMENT	41
<i>,MohdMabood Khan, Mahmood Ahmad Khan, Mahboob Ahmad, M Serajuddin Rafat Sultana Ahmed and Shakeel Ahmad Qidwai</i>	
INTRODUCTION	42
EPIDEMIOLOGY	42
WHAT IS AN ALLERGY?	43
FORM OF ASTHMA	43
CONTROL AND SEVERITY OF ASTHMA	43
CATEGORIZATION OF ASTHMA SEVERITY	44
EVALUATING AN ADULT WITH SEVERE ASTHMA	44
ALLERGIC ASTHMA	44
Pathophysiology	44
For example:	45
<i>The Immune Response</i>	46
<i>Mast Cells</i>	47
<i>Eosinophils</i>	48
<i>Monocytes and Macrophages</i>	48
<i>Basophils</i>	48
<i>T-lymphocytes</i>	49
NONALLERGIC (LATE-ONSET/ INTRINSIC) ASTHMA	50
FIBROBLASTS CELLS AND EPITHELIAL CELLS	50
AIRWAY REMODELLING	50

FEATURES OF AIRWAY WALL REMODELING IN ASTHMA	51
PREVENTION	51
CLINICAL MANAGEMENT	51
Diagnosis of Asthma	51
Diagnostic Tests	51
Blood Cells and Serum Biomarkers	52
Sputum Cells and Mediators	52
Exhaled Breath Analysis	52
TREATMENT GOALS	52
ASTHMA TREATMENT PRINCIPLES	52
TREATMENT	53
Bronchodilators	53
Anticholinergics	53
Short-acting Anticholinergics	54
Long Acting Anticholinergics	54
Glucocorticoids (GC)	54
Methylxanthines	55
Leukotriene Receptor Antagonists and Synthase Blockers	55
Combination Therapy	55
Biologics in Asthma – Next Step of Treatment and their Experience in Severe Asthma	56
<i>Omalizumab (IgE-directed Treatment)</i>	56
Mepolizumab (Eosinophil-targeted Treatment)	57
Secukinumab and Brodalumab	57
Alternative Approach for Asthma Treatment: A Key Advance in Asthma Care	57
Boswellia	58
Tylophoraasthmatica	58
Nigella Sativa	58
Moringa Oleifera	59
Ailanthus Altissima	59
Allium Sativum	59
Flavonoids	59
Flavone Compounds	59
Baicalin	59
Luteolin	60
Flavonol	60
Natural Products Derived from Animal Sources	61
Animal Sea Source	61
Bullfrog Oil	62
Animals Derived Other by Products	62
Biologically Active Products Obtained from Different Microorganisms	62
CONCLUSION	62
Lesson to be Learnt After Studying this Article	63
CONSENT FOR PUBLICATION	63
CONFLICT OF INTEREST	63
ACKNOWLEDGEMENTS	63
REFERENCES	63
CHAPTER 3 NITROGEN-CONTAINING HETEROCYCLES AS ANTI-ALLERGY AGENTS	76
<i>Chetna Ameta, Sunita Panchawat and Dharmendra</i>	
INTRODUCTION	76
SYNTHESIS OF N-CONTAINING COMPOUNDS AS ANTI-ALLERGIC ACTIVITIES	79

Benzimidazole and Imidazole Derivatives as H1/H2/H3-receptor Antagonist	79
Antihistamine Activity of Synthesized Compounds (16-26)	81
Antihistamine Activity of Synthesized Compounds (31a-j)	83
Antihistamine Activity of Compounds (39a-p)	86
Antihistamine Activity of Compounds (46a-b and 56a-f)	91
Antihistamine Activity of Compounds (61a-n, 62a-d, and 63a-h)	92
Synthesis of Quinazoline Derivatives as H1-antihistaminic Activity	94
Antihistamine Activity and Sedative-hypnotic Activity of Synthesized Compounds (70I-X)	97
Antihistamine Activity and Sedative-hypnotic Activity of Synthesized Compounds (74a-j)	98
Antihistamine Activity and Sedative-hypnotic Activity of Synthesized Compounds (78-82)	100
Antihistamine Activity and Sedative-hypnotic Activity of Synthesized Compounds (90a-j)	102
Antihistamine Activity and Sedative-hypnotic Activity of Synthesized Compounds (96a-j)	105
Antihistamine Activity and Sedative-hypnotic Activity of Synthesized Compounds (100a-e)	107
Synthesis of Triazine Derivatives as antihistamine activity	107
Antihistamine Activity of Synthesized Compounds 102, 103 and 104	108
Antihistamine Activity of Synthesized Compounds 107a-f	111
Synthesis of 2-methylpropanamide and benzamide derivatives of carboxyterfenadine as antihistaminic activity	111
Antihistamine Activity of Synthesized Compounds 108-112	113
Synthesis of Sila-substituted 1,3,4-oxadiazoles as anti-histamine activity	114
Antihistamine Activity of Synthesized Compounds 116a-c and 117a-c	114
CONCLUSION	115
CONSENT FOR PUBLICATION	115
CONFLICT OF INTEREST	115
ACKNOWLEDGEMENTS	115
REFERENCES	115
CHAPTER 4 EXPERIMENTAL AND CLINICAL STUDIES ON THE EFFECTS OF NIGELLA SATIVA AND ITS CONSTITUENTS ON ALLERGIC AND IMMUNOLOGICAL DISORDERS	
<i>Mohammad Hossein Boskabady, Saeideh Saadat and Vahideh Ghorani</i>	121
INTRODUCTION	122
METHOD	123
THE EFFECT OF N. SATIVA ON ALLERGIC AND IMMUNOLOGIC DISORDERS, EXPERIMENTAL STUDIES	123
The Effect of N. Sativa and its Constituents on Animal Models of Allergic Rhinitis and Asthma	123
The Effect of N. Sativa and Its Constituents on other Allergic Disorders	129
The Effect of N. Sativa and Its Constituents on Immunologic Disorders	130
THE EFFECT OF N. SATIVA ON ALLERGIC AND IMMUNOLOGIC DISORDERS, CLINICAL STUDIES	134
The Effect of N. Sativa and Its Constituents on Allergic Disorders	134
The Effect of N. Sativa and Its Constituents on Asthma	137
DISCUSSION	139
CONSENT FOR PUBLICATION	140
CONFLICT OF INTEREST	140
ACKNOWLEDGEMENTS	140
REFERENCES	140
CHAPTER 5 ASPIRIN DESENSITIZATION/CHALLENGE IN PATIENTS WITH CARDIOVASCULAR DISEASES: CURRENT TRENDS AND ADVANCES	
<i>Aysa Rezabakhsh and Hassan Soleimanpour</i>	147

HISTORY OF ASPIRIN	147
THE HISTORY OF CARDIOVASCULAR EFFECT	149
THE HISTORY OF ANTITHROMBOTIC/ANTIPLATELET EFFECTS	150
PHARMACOLOGIC CHARACTERISTICS OF ASPIRIN	151
Chemical Structure	151
Pharmacokinetic Properties	152
Absorption, Distribution, Metabolism, and Excretion (ADME)	152
Aspirin Toxicity	153
Pharmacokinetics Points in Pediatrics and Geriatrics	153
Adverse Effects Associated with Aspirin Consumption	154
ASPIRIN MECHANISMS OF ACTION	154
Complementary Mechanisms	157
CLINICAL APPLICATIONS OF ASPIRIN	157
Coronary Artery Bypass Surgery	157
Cerebrovascular Diseases	158
Venous Thrombosis	159
Peripheral Arterial Disease	159
PROPHYLACTIC EFFECT ON CVD	160
Primary Prevention of Cardiovascular Events	160
HOW DOES ASPIRIN LEAD TO ALLERGIC REACTIONS?	162
ASPIRIN SENSITIZATION IN PATIENTS WITH CVD	166
Oral Aspirin Challenge	167
ASPIRIN DESENSITIZATION IN PATIENTS WITH CVD	167
Aspirin Desensitization Procedure in AERD	169
Two Types of Aspirin Desensitization in Patients with CVD	170
<i>a. Slow Desensitization</i>	171
<i>b. Rapid Desensitization</i>	171
PROSPECTIVE INSIGHTS OF CLINICAL STRATEGIES FOR PATIENTS WITH	
ASPIRIN HYPERSENSITIVITY	173
CONCLUSION	175
LIST OF ABBREVIATIONS	175
CONSENT FOR PUBLICATION	176
CONFLICT OF INTEREST	176
ACKNOWLEDGEMENTS	176
REFERENCES	176
SUBJECT INDEX	190

PREFACE

Frontiers in Clinical Drug Research - Anti Allergy Agents (Volume 5) comprises five comprehensive chapters on various treatment strategies for allergic conditions.

In chapter 1, Ozkan and Bakar Ates have discussed the multi-faceted roles of resistin in cellular events as well as its contribution to allergic and inflammatory diseases. Khan *et al.*, in chapter 2 of the book have focused on asthma in adults, its evaluation, prevalence, and clinical management. In the next chapter, Ameta *et al.*, discuss the role of nitrogen-containing heterocycles as anti-allergy agents. Boskabady *et al.*, in chapter 4, present the experimental and clinical studies on the effects of *Nigella sativa* and its constituents on allergic and immunologic disorders. In the last chapter, Rezabakhsh and Soleimanpour summarize the new achievements and novel findings of recent clinical advances related to the desensitization approaches following aspirin consumption in patients with coronary artery diseases (CADs).

I hope that this volume will be of great interest to the scientific community and will play a vital role in the development of more effective therapeutic agents to combat various pulmonary ailments.

I would like to thank all the authors for their contributions and the excellent team of Bentham Science Publishers, particularly Mr. Mahmood Alam (Editorial Director) and Ms. Asma Ahmed (Senior Manager Publications), for their support and hard work.

Prof. Atta-ur-Rahman, FRS
Kings College
University of Cambridge
Cambridge
UK

List of Contributors

Aysa Rezabakhsh	Cardiovascular Research Center, Tabriz, Iran
Chetna Ameta	Department of Chemistry, Udaipur (Raj.), India
Dharmendra	Department of Chemistry, Udaipur (Raj.), India
Erva Ozkan	Faculty of Pharmacy, Department of Biochemistry, Ankara, Turkey
Filiz Bakar Ates	Faculty of Pharmacy, Department of Biochemistry, Ankara, Turkey
Hassan Soleimanpour	Emergency Medicine Research Team, Tabriz, Iran
M Serajuddin	Department of Zoology, Lucknow, U.P. 226007, India
Mahboob Ahmad	Department of Biochemistry, Sitapur, U.P. 261001, India
Mahmood Ahmad Khan	Department of Biochemistry, Dilshad Garden, Delhi 110095, India
Mohammad Hossein Boskabady	Applied Biomedical Research Center, Mashhad-9177948564, Iran Department of Physiology, Faculty of Medicine, Mashhad, Iran
MohdMabood Khan	Department of Zoology, Lucknow, U.P. 226007, India
Rafat Sultana Ahmed	Department of Biochemistry, Dilshad Garden, Delhi 110095, India
Saeideh Saadat	Applied Biomedical Research Center, Mashhad-9177948564, Iran Department of Physiology, Zahedan, Iran
Shakeel Ahmad Qidwai	Department of Orthopaedic, Sitapur, U.P. 261001, India
Sunita Panchawat	Department of Pharmaceutical Sciences, Udaipur (Raj.), India
Vahideh Ghorani	Applied Biomedical Research Center, Mashhad-9177948564, Iran Clinical Research Unit, Faculty of Medicine, Mashhad, Iran

CHAPTER 1

Resistin: An Irresistible Therapeutic Target for Inflammatory Diseases, Allergy-Related Disorders, and Cancer**Erva Ozkan^{1,*} and Filiz Bakar Ates¹**¹ *Ankara University, Faculty of Pharmacy, Department of Biochemistry, Ankara, Turkey*

Abstract: Resistin is a cytokine that has gained popularity over the last decade for its roles in allergic and inflammatory reactions. It is a cysteine-rich protein secreted mostly by macrophages in humans and adipocytes in mice. It was first identified as a small molecule that mediates insulin resistance in rodents. Following the discovery of resistin, many researchers have started investigating its activity in a wide range of pathological conditions where inflammation is present. Findings from these studies have revealed that resistin serves a major function in almost all inflammatory diseases. Elevated serum resistin levels have been associated with allergic contact dermatitis, atherosclerosis, osteoarthritis, obesity, neurological and cognitive disorders, and cancer. Therefore, it is critically important to understand the exact role of resistin in these pathological conditions to develop an effective therapeutic approach. So far, four receptors are known to interact with resistin. Two of these receptors, toll-like receptor 4 (TLR4) and adenylyl cyclase-associated protein 1 (CAP1), are present on the membrane of human macrophages. The other two receptors, receptor tyrosine kinase-like orphan receptor 1 (ROR1) and decorin (DCN), are found in mice. Even though it is possible that ROR1 exists in humans, too, there is still an open question regarding other receptors that interact with resistin in humans. However, accumulated data suggest that resistin is involved in multiple signaling pathways *via* binding to TLR4 and CAP1. This chapter aims to elaborate on the multi-faceted roles of resistin in cellular events as well as its contribution to allergic and inflammatory diseases with a focus on cancer formation based on the current and most recent findings.

Keywords: Adipokines, Allergy, Cancer, CAP1, Cytokines, Diabetes, IL-6, Inflammation, Resistin, TLR4, TNF- α .

* **Corresponding author Erva Ozkan:** Ankara University, Faculty of Pharmacy, Department of Biochemistry, Ankara, Turkey; E-mail: ervaozkan@ankara.edu.tr

INTRODUCTION

In 2001, a group of researchers discovered a unique peptide while investigating adipocyte-derived factors that cause insulin resistance. They named this unique compound 'resistin' because it was highly expressed in obese mice with insulin resistance, and its downregulation improved insulin sensitivity [1]. Following the identification of resistin, the same research group did further analyses to find its homologs based on its unique structure and discovered a family of resistin-like molecules (RELMs) in both humans and rodents. Each identified member of this family (resistin, RELM α , RELM β) was found in different tissues with possible different functions [2]. Interestingly, a different research group discovered the same family of proteins simultaneously while screening for molecules associated with allergic inflammation in mice with ovalbumin-induced asthma, and they named these novel compounds 'found in inflammatory zone' or FIZZ in short [3].

In the decade following the discovery of resistin, numerous studies were conducted in order to illuminate its roles and functions in the pathogenesis of various inflammatory disorders. Data obtained so far have demonstrated a potential benefit in targeting resistin in metabolic diseases in which immune cells are most active. This chapter aims to present current findings regarding the role of resistin in inflammatory and allergic disorders as well as its association with cancer development.

RESISTIN

Structure and Function

Resistin is a 12.5 kDa polypeptide that consists of 108 amino acids in humans and 114 in mice. It was the first identified member of the RELM family. The other members, RELM α , RELM β , and RELM γ , are found in different tissues with diverse functions. Among these, only resistin and RELM β exist in humans [4].

The general structure of resistin, as well as the other RELM proteins, consists of 3 main domains: a cleavable N-terminal signal sequence, a variable middle section, and a cysteine-rich conserved C-terminal region (Fig. 1) [2, 5]. The C-terminal, which constitutes almost half of the entire molecule, is the signature sequence that makes RELM members unique peptides and is responsible for stabilizing the structure as well as binding to receptors [2, 6]. It has been reported that resistin and RELM β contain an additional cysteine residue in N-terminal, which is necessary for multimerization. Due to this extra cysteine, resistin can have a trimer and a hexamer form by disulfide bonding, both of which can be found in serum [7]. The diversity of RELM proteins can be attributed to different coding genes (RETN) present in different species. For instance, mice have four different

RETN genes (Retn, Retn1a, Retn1b, Retn1g), while humans have two (Retn and Retn1b) [4]. Furthermore, single nucleotide polymorphisms of RETN have been reported in humans and are associated with varying impacts on metabolic disorders such as obesity and diabetes [8].




Fig.(1). A representation of the structure of resistin in monomer, trimer, and hexamer forms.

Current data on the function of RELM proteins are very limited. However, resistin has received much attention and has been well-studied in recent years due to its close relationship with inflammation and diverse roles in various pathologies. So far, 4 receptors have been reported to interact with resistin: toll-like receptor 4 (TLR4), adenylyl cyclase-associated protein 1 (CAP1), receptor tyrosine kinase-like orphan receptor 1 (ROR1), and decorin (DCN). In humans, mainly TLR4 and CAP1 receptors are expressed, while the other two are predominantly found in mice [4]. These receptors and their downstream signaling pathways have been explored in numerous studies and are still being investigated for their potential to develop new treatment strategies. The binding of resistin to TLR4 stimulates TNF receptor-associated factor 6 (TRAF6) *via* the MyD88-dependent signaling pathway, leading to the phosphorylation and activation of p38mitogen-activated protein kinase (MAPK) and nuclear factor- κ B (NF- κ B) signaling pathways. Resistin can also activate p38-MAPK and NF- κ B *via* binding to CAP1, which then upregulates cyclic AMP (cAMP) concentration and protein kinase A (PKA)

CHAPTER 2

Asthma in Adults: Evaluation, Prevalence, and its Clinical Management

MohdMabood Khan¹, Mahmood Ahmad Khan^{2,*}, Mahboob Ahmad^{3,*}, M Serajuddin¹, Rafat Sultana Ahmed² and Shakeel Ahmad Qidwai⁴

¹ Department of Zoology, University of Lucknow, Lucknow, U.P. 226007, India

² Department of Biochemistry, UCMS & GTB Hospital, Dilshad Garden, Delhi 110095, India

³ Department of Biochemistry, Hind Institute of Medical Sciences, Sitapur, U.P. 261001, India

⁴ Department of Orthopaedic, Hind Institute of Medical Sciences, Sitapur, U.P. 261001, India

Abstract: Asthma is among the world's most common severe lung disorders, affecting one-third of the world's population with incidence ranging from 4.9% to 12.7%. Around 3.5 million people die annually due to the worse health effects of asthma. Men (6.2%) have been seen to be less prevalent than women (10.4%) internationally. As a product of inflammation and super sensitivity, asthma is a multifactorial condition with symptoms such as cough, shortness of breath, wheezing, and chest pain. There are a number of agents that may be responsible for the development of asthma. This includes air pollution, obesity, bacteria, viruses, fungi, flu germs, dust, pollen, tobacco, smoking, exercise, depression, anxiety, allergic agents, physical and emotional stress. Depending on the susceptibility of the individual, asthma showed mild to serious results. For a deeper understanding of disease pathogenicity, mechanistic mechanisms should concentrate on a number of aspects like metabolic abnormalities, molecular genetics, inflammatory asthma complexity, *etc.* Commensal micro biota is one of the main factors that cures disease and has a major role in balancing the immune system in the gut and lung. In addition to the foregoing, potential indicators include serum IgE, a number of bloodstream eosinophil or levels of sputum eosinophil, FeNO (fractional exhaled nitric oxide), and serum periostin are presently employed in the asthma diagnosis. The two key therapies available on the basis of disease severity for patients are oral corticosteroids and bronchodilators. However, steroid-based therapy has certain side effects, such as elevated BP, adrenal suppression, and bone weakening. Due to this, we should target non-steroid medications, including anti-cholinergic medication (Tiotropium) and biological therapy. For serious asthma patients, various new medications (such as Anti-IL-4, Anti-IL-5, Anti-IL-13, and Anti-IgE therapy) have been used and found effective. To select the right medication and system for a better

* Corresponding authors Mahmood Ahmad Khan and Mahboob Ahmad: Department of Biochemistry, UCMS & GTB Hospital, Dilshad Garden, Delhi 110095, India and Department of Biochemistry, Hind Institute of Medical Sciences, Sitapur, U.P. 261001, India; Tel: +918918018776, +918882218233; E-mails: mahmood.khan876@gmail.com, mahboobalig@gmail.com

treatment plan, asthma patient requires proper review such as guidance, constancy, advice, drug alert, refill warning, notification warning, *etc.*

Keywords: Allergy, Anti-Cholinergic, Asthma, Biomarkers, Bronchodilators, Corticosteroids, Immunesystem, Inflammation, Micro biota, Wheezing.

INTRODUCTION

Allergic diseases are widespread, can have a major effect on a patient's physical and mental health ultimately affecting an individual's standard of living. Recent epidemiological studies show that the prevalence of such diseases is still increasing and they discover novel signs and symptoms for the progression of disorder (atopic/allergic) in youngsters [1, 2]. It is found in both well-established [3] and emerging [4] countries, bolstering the notion that asthma is partly an allergenic condition. Asthma is a severe lung disorder that is marked by bronchial hyper-responsiveness, reversible airflow restriction, and symptoms such as wheezing, chest tightness, and cough [5]. These symptoms are frequently episodic in nature and can differ in severity due to changes in stimuli, including allergens, airway pathogens, or respiratory illnesses such as allergic rhinitis and sinusitis [6]. Upper airway symptoms should be elicited because they may reflect different presentations of similar allergy aetiology.

Asthma accounts for about 1.1% of all disability adjusted life years (DALYs) loss globally [7]. According to the latest statistics, 623 million individuals suffer from asthma related symptoms, with 250,000 individuals who die every year as a result of this disease [8]. Asthma is projected to have the highest economic losses among chronic disease patients due to high healthcare use. Many studies have indicated that poor asthma regulation, individual vulnerability, fungal inflammation, pathogen consumption, ambient tobacco smoke (ETS) susceptibility, and exposure to air pollution from ozone (O₃), sulphur dioxide (SO₂), nitrogen dioxide (NO₂), and particle matter (PM) cause or aggravate asthma [9]. New treatments such as omalizumab for asthma and urticaria have been tested and approved in recent years, which have now become real-life experiences for patients and clinicians, are providing long-term data.

EPIDEMIOLOGY

Asthma is significantly more prevalent in females (10.4%) who had much higher rates of asthma related to males (6.2%) [10]. The prevalence varies significantly from 4.9% to 12.7% geographically [11]. Asthma is traditionally considered to be a disease that starts in the youth. Despite the fact that asthma has been most commonly diagnosed in children, this could develop significantly at whatever

time of life. According to national data, the incidence of asthma first appears in people over the age of 65, which have a 7% prevalence of asthma in comparison to overall asthma cases. Precocious history, initial chest infections, rhinitis, tobacco, and overweight have all been associated with adult-onset asthma [12].

WHAT IS AN ALLERGY?

Your immune system is in charge of protecting yourself against germs and viruses. Meanwhile, when you do have allergies, a part of our defense system is overworked. This can target innocuous things inside your nasal, chest, eyeballs, and under your skin like cat dander or pollen. When the body is exposed to an allergen, it (body) produces molecules known as IgE antibodies. Substances such as histamine are also released, which cause swelling and inflammation. When your body attempts to eliminate the allergen, a sign including a bad cold, eye irritation, and coughing can occur.

FORM OF ASTHMA

There are two forms of asthma that usually affect adults. The first form of asthma is allergic asthma/ Early-onset asthma which is closely linked to allergens. Early-onset asthma is asthma that begins during puberty and is typically followed by allergic rhinitis and/or atopic dermatitis. The second form of asthma is intrinsic (eosinophilic) asthma/ Adult-onset or late-onset asthma which frequently develops in adulthood and is unrelated to allergens [13]. Increased levels of certain types of cytokines and eosinophil granulocytes in both forms of asthma, as well as structural cell abnormalities, are found.

CONTROL AND SEVERITY OF ASTHMA

Asthma control is the main objective of treatment, and to fulfil this objective, a lot of weight is given to the clinical setting. For the assessment of disease management, various questionnaire forms have now been approved [14 - 17]. The Asthma Therapeutic Assessment Questionnaire (<http://www.asthmacontrol-check.com/asthmacontrol/asthmacontrolcheck/consumer/index.jsp>) [18], the Asthma Management Questionnaire ([http://aafa.org/pdfs/SWP percent 20final% 20questionnaire.pdf](http://aafa.org/pdfs/SWP_percent_20final%20questionnaire.pdf)) [19], and an Asthma Control Test (<http://www.asthmacontrol.com>) [20] give verified asthma regulate “scores” which could be useful to categorise asthma in three groups: well controlled, not well controlled, and extremely poorly controlled [21].

According to disease management standards, determining the pathogenicity is necessary to begin treatment and maintain it in a step-by-step way [22]. Misinterpretation of severities can result in either misuse or excessive use of anti-

Nitrogen-containing Heterocycles as Anti-allergy Agents

Chetna Ameta^{1,*}, Sunita Panchawat² and Dharmendra¹

¹ Department of Chemistry, Mohan Lal Sukhadia University, Udaipur (Raj.), India

² Department of Pharmaceutical Sciences, Mohan Lal Sukhadia University, Udaipur (Raj.), India

Abstract: Nitrogen-containing heterocycles exhibit a diverse range of biological activities and are widely explored and utilized by the pharmaceutical industry for drug discovery. There are a lot of synthesized N-Containing heterocyclic compounds that showed antiallergic/antihistamine activities. A series of imidazole derivatives (Such as cimetidine), benzimidazole derivatives (Such as Astemizole, Bilastine, Emedastine, Mizolastine, and Clemizole), and 2-methylpropanamide and benzamide derivatives of carboxyterfenadine are synthesized and evaluated as H₁ antihistamine activity. Quinazolinone derivatives, pteridinones related compounds, and piperidine derivatives (such as Fexofenadine) also have strong antihistamine activity with a low sedative effect. Antihistaminic activity of the synthesized compounds was studied on the histamine-induced contractions of guinea-pig ileum tissues.

Keywords: Anti-allergic, Antihistaminic, Drugs, Heterocycles, Nitrogen.

INTRODUCTION

Histamine is a physiologically active β -imidazolyethylamine derivative found in many tissues, including mast cells, basophils, lymphocytes, neurons, and gastric enterochromaffin-like cells [1 - 4]. Histamine is a major mediator of the allergic and inflammatory process and also has significant roles in regulating gastric acid secretion, neurotransmission, and immune modulation [5]. It is synthesized from the amino acid histidine in a decarboxylation reaction with the enzyme histidine decarboxylase [6, 7]. Histamine exerts its actions by combining with specific cellular receptors located on cells. Histamine receptors belong to the family of G-protein coupled receptors (GPCRs). The subtypes of histamine receptors are H₁, H₂, H₃, and H₄ [8 - 15].

* Corresponding author Chetna Ameta: Department of Chemistry, Mohan Lal Sukhadia University, Udaipur (Raj.), India; E-mail: chetna.ameta@yahoo.com

H₁ receptor is found on endothelial cells, smooth muscle, heart, adrenal medulla, and CNS [16]. It causes bronchoconstriction, vasodilation, separation of endothelial cells (responsible for hives), local tissue redness and swelling, *etc.* H₂ receptor is located on gastric parietal cell, vascular smooth muscles, and CNS. It regulates gastric acid secretion and inhibits IgE-dependent degranulation. H₃ receptor distributed in central and peripheral nerve endings of the presynaptic membrane inhibit histamine synthesis and release. H₄ receptor is highly expressed in bone marrow, spleen, small intestine, and WBC. It plays a role in chemotaxis [5, 16 - 23].

Allergy is defined as an overreaction of the immune system to external harmless substances (allergens). The common allergens are pollen, dust, animal dander, mites, chemicals, drugs, insect venom, and various foods. The common allergic reactions include skin redness and swelling, itching, rash, patches, allergic rhinitis, laryngeal edema, systemic anaphylaxis, bronchial asthma, atopic dermatitis, and other symptoms [24 - 30].

A drug that reduces or blocks the effects of chemical mediators (in particular Histamine) of mast cells is called antihistamine (H₁ receptor antagonists)/anti-allergic drugs. Currently, the H₁ receptor antagonists are used in clinical practice as anti-allergic drugs. The H₁ antagonists are mainly classified into three types:

- i. **First-generation H₁ receptor antagonists**- these are the classical drugs such as piperazine derivatives (cyclizine & meclizine), propylamine derivatives (chlorpheniramine), and ethylenediamine derivatives (tripelennamine & methapyrilene), *etc.* The main adverse effect of 1st generation antagonist is sedation and cross the blood-brain barrier.
- ii. **Second-generation H₁ receptor antagonists**- these are largely free from sedation and do not cross the blood-brain barrier. For example- fexofenadine, loratadine, desloratadine, levocetirizine, cetirizine, azelastine, *etc.*
- iii. **Third generation (newer) H₁ antagonist** s- these are active metabolite derivatives or active optical isomers of second-generation drugs. They are safe and have minimum side effects [31 - 34].

Most of the drugs belong to the class of heterocyclic compounds. Heterocyclic compounds played a vital role in medicinal chemistry. Among heterocyclic compounds, the nitrogen-containing heterocycles exhibit a diverse range of biological activities and are widely explored and utilized by the pharmaceutical industry for drug discovery.

Several synthesized five and six-membered N-containing heterocyclic compounds have shown anti-allergic/anti-histamine activities. The structures of many

marketed drugs that are recently used as anti-histamine drugs are bilastine, astemizole, mizolastine, emedastine, clemizole (benzimidazole derivatives), cimetidine (imidazole derivatives), cetirizine and fexofenadine (piperidine derivatives), *etc.* All these molecules contain different N-heterocyclic moieties (Fig. 1) [31, 33, 35 - 39].




Fig. (1). Structure of some antihistamine drugs available in the market.

This chapter mainly focuses on the research progress, design, and synthesis of various new N-containing compounds as anti-allergic drugs.

CHAPTER 4**Experimental and Clinical Studies on the Effects of *Nigella Sativa* and its Constituents on Allergic and Immunological Disorders****Mohammad Hossein Boskabady^{1,2,*}, Saeideh Saadat^{1,3} and Vahideh Ghorani^{1,4}**¹ Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad-9177948564, Iran² Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran³ Department of Physiology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran⁴ Clinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract: Various pharmacological effects were shown for *Nigella sativa* (*N. sativa*), including anti-inflammatory, antioxidant, and immunomodulatory properties. The plant also has been used in traditional medicine for the treatment of various diseases. In this chapter, the effects of *N. sativa* and its constituents in allergic and immunologic disorders based on the experimental and clinical studies are provided. Articles published on the effect of *N. sativa* and its constituents on allergic and immunologic disorders in the experimental and clinical studies were searched until July 2020. For this purpose, keywords including; *Nigella sativa*, black seed, thymoquinone, alpha-hederin, carvacrol, allergic disorders, and immunology disorders were searched in different databases such as PubMed, Science Direct, Scopus, and Google Scholar. Experimental studies showed various immunologic effects of *N. sativa* extracts and their constituents, including their effects on Th1/Th2/ balance. Treating patients with *N. sativa* seed, alleviate symptoms of allergic rhinitis and decrease the body temperature in allergic patients which is due to immunomodulatory properties of the plant. Treatment of Vitiligo patients with *N. sativa* also reduced the Vitiligo Area Scoring Index (VASI). Various studies showed that *N. sativa* and its constituents showed significant effects on allergic and immunologic disorders. Therefore, *N. sativa* and its constituents could be good candidate drugs for treating allergic and immunologic disorders.

* **Corresponding author M.H. Boskabady:** Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad-9177948564, Iran and Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; E-mail: boskabady@ums.ac.ir

Atta Ur Rehman, FRS (Ed.)

All rights reserved-© 2022 Bentham Science Publishers

Keywords: Alpha-hederin, Allergic disorders, Carvacrol, Clinical studies, Experimental studies, *Nigella sativa*, Immunologic disorders, Thymoquinone.

INTRODUCTION

Nigella sativa (*N. sativa*), known as 'Black Seed,' is an annual flowering plant in the family Ranunculaceae, native to a large region of Southern Europe, North Africa, and Southwest Asia [1]. It grows to 20-90 cm tall and has divided green leaves, delicate, pale blue, and white flowers. Its seeds are named as 'Black Seed' or 'Black Cumin' in English, 'Habba Al-Sauda' or 'Habba Al-Barakah' in Arabic, 'Kalonji' in Urdu, 'Siyah Daneh' in Persian, and 'Corek Out' in the Turkish language. The scientific name is a derivative of Latin 'niger', meaning 'black' [2].

Chemical analysis of the plant seeds has demonstrated that oils, proteins, carbohydrates, fibers, ashes, moisturizers, *etc.*, are the plant's general compound [3]. Non-oily and non-caloric components of the plant consist of phyto-alkaloids, including pyrazol (nigellidine and nigelline), isoquinoline (nigellimine and nigellimine-N-oxide) as well as a flavonoid (Comferol), diglucoside and digalactoside, alpha-hederin, saponins, vitamins (riboflavin, pyridoxine, niacin, thiamin, folic acid and vitamin E and minerals (sodium, potassium, calcium, magnesium, copper, iron, and phosphorus) [4, 5]. The oil component of *N. sativa* mostly consisted of inoleic, palmitic, oleic, dihomolinoleic, and eicodadienoic acids [5 - 7]. The most essential pharmacologically active compounds in the plant's essential oil are thymoquinone (TQ), thymohydroquinone, dithymoquinone, p-cymene carvacrol, 4-terpineol, t-anethol, sesquiterpene longifolene α -pinene, and thymol [8].

In the acute and chronic toxicity studies using animal models, *N. sativa* and its oil are commonly considered safe, particularly when given orally [2, 9, 10].

N. sativa is an extensively used medicinal plant throughout the world. Traditionally, *N. sativa* is used in the treatment of various diseases such as cough, bronchitis, asthma, chest congestion, chronic headache, migraine, dizziness, infertility, paralysis, rheumatism, back pain, hemiplegia, fever, dysmenorrhea, obesity, diabetes, hypertension, infection and inflammation, flatulence, dyspepsia, and diarrhea [3, 8, 11]. In traditional medicine, this plant's administration, combined with honey, also improved respiratory diseases such as chest congestion, asthma, and bronchospasm [12]. *N. sativa* and its ingredient showed a variety of pharmacological activities such as a diuretic [8], antidiabetic [13], antihypertensive [14], anti-inflammatory [15], antioxidant [16], immunomodulatory [17], hepatoprotective [18], renal protective [19], gastroprotective [20], and bronchodilator properties [21, 22]. Black seeds were also used against various disease including allergy, bronchial asthma, respiratory distress, and lung

infection [23]. Therefore, in this chapter, an updated overview of the experimental and clinical studies on the effects of *N. sativa* and its constituents on allergic and immunologic disorders is provided.

METHOD

Different databases, including PubMed, Science Direct, Scopus, and Google Scholar were searched for finding articles published on the effect of *N. sativa* and its constituents on allergic and immunologic disorders in the experimental and clinical studies until July 2020. Keywords, including; *Nigella sativa*, black seed, thymoquinone, alpha-hederin, carvacrol, allergic disorders, and immunology disorders were used.

THE EFFECT OF *N. SATIVA* ON ALLERGIC AND IMMUNOLOGIC DISORDERS, EXPERIMENTAL STUDIES

The Effect of *N. Sativa* and its Constituents on Animal Models of Allergic Rhinitis and Asthma

The effect of *N. sativa* in different immune and inflammatory parameters was evaluated in various models of allergic asthma. In ovalbumin (OVA)-sensitized guinea pigs, the hydro-ethanolic extract of *N. sativa* (0.125 and 0.25 mg/ml) reduced tracheal responsiveness to methacholine and WBC counts in bronchoalveolar lavage fluid (BALF) [24].

Sensitized mice treated with *N. sativa* in food showed a significant decrease in the number of eosinophils, and a potential inhibitory effect on the mRNA expression level of Th2-driven immune response cytokines and mucin in the BALF, resulting in decreased production of the interleukin and mucin in allergic asthma [25].

Administration of *N. sativa* oil (5 ml/kg) in ovalbumin-sensitized mice reduced the peripheral blood eosinophil count, IgG1 and IgG2a levels, cytokine profiles, and inflammatory cells in the lung tissue [26, 27].

In a model of OVA-induced bronchial asthma in mice, oral treatment with *N. sativa* oil (1 and 4 ml/kg) showed a significant decrease in the tracheal responsiveness (TR), total white blood cell (WBC) count, macrophages and eosinophils, the BALF levels of IL-4, IL-5 and IL-13, the serum levels of total IgE, OVA-specific IgE and IgG1, and a significant increase in the BALF level of IFN- γ and the serum level of OVA-specific IgG2a, indicating a restoration of local Th1/Th2 balance [28].

CHAPTER 5**Aspirin Desensitization/Challenge in Patients with Cardiovascular Diseases: Current Trends and Advances****Aysa Reza bakhsh¹ and Hassan Soleimanpour^{2,*}**¹ Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran² Emergency Medicine Research Team, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract: Aspirin, known as acetylsalicylic acid (ASA), is one of the most commonly used medications. Available as over-the-counter medicine, ASA is prescribed as a nonsteroidal anti-inflammatory and anti-platelet drug and has the potential to decrease pain and fever. ASA is also considered as a first-line drug for the treatment of some cardiovascular diseases such as coronary artery diseases (CAD) and myocardial infarction (MI). Subsequently, it has been demonstrated to reduce the morbidity and mortality rate of these diseases. Besides the beneficial effects, ASA has the potential to provoke some allergic reactions, particularly in patients with CAD. According to previous reports, in 1.5-2.6% of the subjects with CVD treated with ASA, aspirin-exacerbated respiratory disease or chronic idiopathic urticaria were observed. In this book chapter, we aimed to summarize all-new achievements and novel findings of recent clinical advances related to the desensitization approaches following aspirin consumption in patients with CADs

Keywords: Acetylsalicylic Acid, Allergic Reactions, Anti-Platelet Effects, Anti-thrombotic effect, Aspirin (ASA), Aspirin Challenge, Aspirin Desensitization, Aspirin-Induced Exacerbated Respiratory Disease (AERD), Cardiovascular Disease (CVD), Clinical Advances, Clinical Trials, Coronary Artery Diseases (CAD), Cyclooxygenase (COX), Hypersensitivity, Leukotriene, Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Prostaglandins, Rapid Desensitization, Sensitivity, Slow Desensitization.

HISTORY OF ASPIRIN

Aspirin is one of the most commonly used and popular pharmaceutical agents of the last 100 years. It is a synthetic derivative of salicylic acid, and as a natural

* **Corresponding author Hassan Soleimanpour:** Emergency Medicine Research Team, Tabriz University of Medical Sciences, Tabriz, Iran; Tel: +989141164134; Fax: +984133352078; E-mails: h.soleimanpour@gmail.com & soleimanpourh@tbzmed.ac.ir

product, found in willow tree bark, grains, and some fruits [1]. The name of aspirin was originally derived from the plant source of salicylic acid, and the synthesis process involved: the letter *A* originated from *acetyl chloride*, and the *spirin* originated from the genus name of *Spiraea ulmaria* plant, which is a rich source of salicin [2]. In Table 1, the ancient history and the uses of salicylate acid (ASA) containing plants are shown:

Table 1. The ancient history of aspirin.

Scientist/ Civilization	Year	Plant/Agent	Outcomes	Ref.
Sumerians, Assyrians and the Egyptians	4000 BC	The leaves of the willow tree	Analgesic and antipyretic effects	[3]
Ebers Papyrus	1300 to 1500 BC	Willow plant and myrtle	Inflammatory, antipyretic, and analgesic effects	[4]
Celsus, Pliny and Hippocrates	460 to 377 BC	Chewing brewed tea made of willow bark	Antipyretic and analgesic effects	[5,6]
Dioscorides	100 CE	Willow bark	Treatment of colic, gout and earache	[7]

Abbreviation: BC: Before Christ, CE: Christian Era.

Once the beneficial effects of salicylate (salicylic acid) were explored, scientists intended to isolate it from the bark in the early-19th century. In Table 2, the modern history of aspirin is summarized:

Table 2. The modern history of aspirin.

Scientist/Country	Year	Plant/Agent	Outcomes	Ref.
R. Edward Stone	1763	Willow-bark	Treatment of Ague (a fever from malaria)	[8]
F. Fontana and B. Rigatelli	1824	Willow-bark	The extraction of bioactive components	[9]
J. Buchner	1828	Willow-bark	Salicin isolation	[10]
H. Leroux	1829	Willow-bark	Analgesic effects	[10]
R. Piria	1838	Aspirin	Synthesizing salicylic acid in a crystal form	[10]
Charles .F. Gerhardt	1853	Aspirin	Exposing the acetyl chloride with sodium salicylate, Synthesizing acetylsalicylic acid	[7]
H. Kolbe	1859	Aspirin	Discovering the salicylic acid chemical structure, Side effects observation <i>e.g.</i> gastrointestinal irritation	[11]

(Table 4) cont....

Scientist/Country	Year	Plant/Agent	Outcomes	Ref.
F. Heyden	1874	A synthetic form of salicylic acid	Industrial production	[12]
T. MacLagan	1876	Salicin consumption	Planned the first clinical trial for acute rheumatism treatment published in <i>The Lancet</i> journal	[13]
F. Hoffmann	1897	Salicylic acid chemical structure modification	Synthesize a derivative of salicylates without any side effect	[13]
F. Bayer	1899	Aspirin	Tradename Registration	[6]
U.S.	1900	Aspirin	Drug Patented	[14]
U.S.	1904	Aspirin	Stamped tablet production	[15]

THE HISTORY OF CARDIOVASCULAR EFFECT

Previous findings regarding the antithrombotic property of aspirin between the 1950s and 1960s proposed that aspirin could be an effective agent for the prevention of possible cardiovascular events [16]. Herein, we outlined the historical issues in this setting:

Table 3. The clinical trial studies on the protective role of aspirin against CVDs.

Author/Organization	Year	Study Type	Outcomes	Ref.
P. Elwood	1974	Randomized controlled trial, single dose of aspirin (300 mg daily), 1,239 patients with MI	Significant reduction in total mortality of 12% and 25% after 6 and 12 months, respectively.	[17]
R. Peto	1980	Meta-analysis on over 10,000 patients with MI	Aspirin potentially decreased the risk of re-infarction by 21% in patients.	[18]
ISIS-2 Collaborative Group	1988	17,187 patients with re-infarction (162 mg aspirin daily for 1 month)	RRR in patients diminished, up to 23% in aspirin and the mortality rate dropped to 9.4%	[19,20]
FDA	1985	–	Aspirin was approved for secondary prevention of acute MI	[14]
AHA, ACC	2019	Modification of clinical practice guidelines	Routine administration of aspirin in subjects aged over the 70	[21]

Abbreviation: ACC: American College of Cardiology; AHA: American Heart Association, FDA: Food and Drug Administration; ISIS-2: Second International Study of Infarct Survival, MI: Myocardial Infarction; RRR: Relative Risk Reduction.

SUBJECT INDEX

A

- Absorption, distribution, metabolism, and excretion (ADME) 152
- Acetic anhydride 151
- Acetylcholine 53, 54, 124, 126, 127
neurotransmitter 53
- Acid(s) 2, 97, 99, 106, 111, 114, 122, 147, 148, 149, 151, 152, 154, 155
acetic 97, 99, 106, 111, 114, 151
acetylsalicylic 147
amino 2
arachidonic (AA) 151, 154, 155
butyric 97, 99, 106
eicodadienoic 122
folic 122
formic 97, 99, 106
mercaptoacetic 114
propionic 97, 99, 106
salicylate 148
salicylic 147, 148, 149, 151, 152
- Acidosis 152
- Activation of Akt and fatty acid synthase 23
- Activity 1, 16, 22, 25, 58, 61, 62, 82, 94, 101, 103, 106, 107, 114, 130, 156, 162
anti-asthma 62
anti-histamine 114
anti-histaminic 107
anti-platelets 156
anti-tumor 130
immunological 162
inhibiting hexokinase 16
- Adipocytes 1, 12
- Adipocyte secretome 24, 25
obesity-associated 24
- Adipokine(s) 1, 6, 12, 16, 24
dysregulation 6
obesity-associated 24
- Adrenocorticotrophic hormone 135, 137
- Agents 41, 54, 63
cholinergic 54
- Airways 47, 48, 50, 53, 54, 55, 56, 59, 126, 134, 137, 169, 170
chitin-induced 126
disorders 170
inflammation 50, 53, 55, 59
- Allergen 46, 51
absorption 46
provocation test 51
- Allergic 2, 16, 17, 18, 20, 22, 29, 42, 43, 44, 45, 46, 49, 50, 58, 60, 115, 121, 122, 123, 124, 126, 129, 134, 135, 136, 140, 147, 162, 163, 165, 166, 168
airway inflammation 50
asthma 16, 17, 43, 44, 49, 50, 123, 136
bronchopulmonary aspergillosis 18, 136
conjunctivitis treatment 140
diseases 17, 42, 58, 60, 115, 135
disorders 2, 16, 17, 22, 29, 121, 122, 123, 129, 134, 136
hypersensitivity 162
reactions 16, 45, 136, 147, 162, 163, 165, 166, 168
rhinitis (AR) 16, 17, 18, 20, 22, 42, 43, 121, 124, 126, 134, 135, 136
sensitization 46
- Allergic inflammation 2, 17, 18, 22, 48
asthmatic 48
- Allergy 1, 42, 43, 58, 77, 122, 125, 132
aetiology 42
- Allium Sativum* 59, 61
- Alzheimer's disease 16
- AMP-activated protein kinase 4, 8, 24
- Anatomic anomalies 44
- Angioedema 165, 166, 168
reactions 165
- Angiogenesis 12, 13, 18, 22, 24, 25, 27
- Angiography 171, 172
coronary 171
- Angiotensin-converting enzyme inhibitors (ACEIs) 156
- Anthracycline chemotherapeutic agent 28
- Anti-allergic 17, 58, 79, 114, 134, 136

- activities 58, 79, 114
 - effects 134, 136
 - therapies 17
 - Antiasthma action 60
 - Anticholinergic agent 54
 - Antigen presenting cells (APCs) 12, 17
 - Antihistamine activity 76, 89, 91, 97, 98, 100, 102, 105, 107, 108, 111
 - and sedative-hypnotic activity 97, 98, 100, 102, 105, 107
 - Antihistamines 55, 77, 89, 111, 169
 - Antihistaminic activity 76, 98, 108, 110, 111, 113
 - Anti-inflammatory 61, 53, 59
 - activity 61
 - glucocorticoids 53
 - properties 53, 59
 - Anti-platelet 147, 151, 156, 170
 - effects 147, 151, 156
 - therapy 170
 - Anti-thrombotic effect 147
 - Apoptosis 60
 - Arthritis 5, 11, 22, 153, 167
 - rheumatoid 5, 11, 22, 153
 - Aspirin 147, 152, 154, 156, 160, 162, 166, 167, 169, 173, 174
 - absorption 152
 - allergic reaction 162
 - consumption 147, 154, 162
 - hypersensitivity 162, 167, 169, 173, 174
 - induced exacerbated respiratory disease 147
 - metabolism 156
 - prophylactic 160
 - sensitization 166
 - Assessment, pulmonary 51
 - Associated cardiovascular complications 11
 - Asthma 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 55, 56, 57, 58, 59, 61, 62, 63, 126, 166
 - airway malfunction 48
 - aspirin-induced 166
 - mild asymptomatic 50
 - refractory eosinophilic 57
 - severity 43, 44
 - stroke 45
 - symptoms 58, 59, 62
 - therapeutic assessment questionnaire 43
 - treatment principles 52
 - Asthmatic 44, 45, 57, 138, 139, 140
 - aggravation 44
 - airways 138
 - inflammation 45, 57
 - symptoms 139
 - Atherosclerosis 1, 9, 11, 159
 - Athero sclerosis 22
 - Atherosclerotic lesions 10
 - Atopic dermatitis 16, 43, 45, 77, 129, 140
 - ATP16, 28
 - binding cassette (ABC) 28
 - production 16
 - Autoimmunity 125
 - Auto-inflammatory syndromes 132
 - Autophagy 28
 - resistin-induced 28
 - resistin-induced pro-survival 28
- B**
- Bacterial lysate 62
 - Basophilic leukemia 131
 - Basophils activity 167
 - Benzimidazole 76, 78, 79, 81, 82, 86, 89, 91, 115
 - and imidazole derivatives 79
 - derivatives 76, 78, 79, 81, 82, 86, 89, 115
 - system 91
 - Binding, muscarinic antagonist 54
 - Bleeding 151, 154, 160, 161, 162, 167
 - complications 161
 - side effects 161
 - Blocking γ -aminobutyric acid activities 60
 - Blood 52, 125, 137
 - cells and serum biomarkers 52
 - cytokines 125
 - eosinophils 137
 - Body plethysmography 51
 - Bone marrow 14, 130, 133
 - lesions 14
 - mitotic index 130, 133
 - Boronchoalevolar lavage fluid 123, 128
 - Brain-penetrating H1-antihistamines 82, 85
 - Breast cancer 20, 23, 25, 26, 28
 - Bronchial 42, 45, 53, 58, 61, 77, 122, 125, 135
 - asthma 58, 77, 122, 125, 135
 - asthma treatment 53
 - hyper-responsiveness 42
 - Bronchitis 60, 61, 122
 - Bronchoalveolar lavage fluid (BLF) 48
 - Bronchoconstriction 47, 77

- Bronchodilation 54, 126
 Bronchodilator 53, 122
 properties 122
 responses 53
 Bronchomotor tone 126
 Bronchospasm 94, 97, 100, 109, 122, 162,
 163, 164, 171
 effect 171
 histamine-induced 94, 97, 100
- C**
- Cancer 19, 20, 23, 29, 160, 161
 colon 23
 colorectal 160, 161
 gastric 20
 ovarian 20
 pancreatic 19, 23, 29
 Cancer cell(s) 25, 27, 28, 29
 adhesion 27
 colon 28
 colorectal 25
 ovarian 28
 pancreatic 29
 resistinoverexpressing lung 25
 Cancer progression 19, 20
 Carboxyterfenadine 76, 111, 115
 Carcinogenesis 20
 Cardio-embolic strokes 158
 Cardiovascular 15, 29, 149, 160, 161, 170
 effect 149
 events 149, 160, 161, 170
 problems 15, 29
 Cartilage 14, 22
 damage 14
 degeneration 22
 Carvacrol treatment 125
 Caspase activity 21
 inhibiting chemotherapy-induced 28
 Cell 4, 17, 27
 adhesion molecules (CAM) 27
 signaling pathways 4
 transformation 17
 Cell growth 21, 60
 and proliferation 21
 arrest 60
 Cell proliferation 12, 21, 22, 23, 24, 27, 126,
 132, 133, 139
 endothelial 27
 reduced 21
 stimulated 21
 Cerebral hemorrhages 160
 Chemoattractant properties 10
 Chemokines 4, 13, 46, 50, 57
 Chemotactic effects 13
 Chemotherapy 27
 Chlorpheniramine maleate 98, 103, 107
 Cholesterol 11, 22, 135
 elevated LDL 11
 Chronic kidney disease (CKD) 15, 153
 Cinnamomum cassia 61
 CNS 94, 109
 depression properties 109
 exposure 94
 Conditions 11, 13, 42, 132
 allergenic 42
 immunologic 132
 inflammatory 11, 13
 Conjunctivitis 129
 Constipation 61
 Coronary artery 147, 157, 168, 169, 170, 174
 bypass surgery 157
 diseases (CAD) 147, 168, 169, 170, 174
 Corticosteroids 17, 41, 42, 44, 48, 54, 138,
 169
 inhaled 17, 44
 oral 41
 Cough 41, 42, 58, 61, 122
 COVID-19 infection 15
 COX 155, 156
 enzymes 156
 inhibitors 155
 isozymes 155
 CVD 160, 161
 events 160
 related risk factors 161
 Cyclic nucleotide phosphodiesterase 55
 Cyclooxygenase 58, 147, 151, 155
 Cysteine residue 2
 Cytokines, inflammatory 4, 13, 50, 57, 59, 60
- D**
- Damage, severe systemic 15
 Death 15, 18, 25, 52, 160, 161
 cancer-related 25
 Deep vein thrombosis (DVT) 159
 Dementia 16, 22
 vascular 16
 Dendritic cells (DCs) 46, 48, 132

- de novo* lipogenesis 6, 11
Dermatitis 1, 18, 129, 136, 166
 allergic contact 1, 18
Desensitization 167, 168, 169, 170, 171, 172, 174
 aspirin-based 170
 procedure 167, 170, 171, 172
 process 169
Diagnostic tests 51
Diarrhea 122, 129, 139
 murine allergic 139
Disability, knee 15
Disease(s) 11, 12, 13, 15, 18, 21, 22, 23, 24, 29, 41, 42, 43, 44, 45, 46, 48, 50, 51, 56, 58, 121, 122, 132, 147, 153, 157, 158, 159
 aspirin-exacerbated respiratory 147
 autoimmune 11, 132
 cerebrovascular 157, 158
 chronic kidney 15, 153
 chronic obstructive pulmonary 46, 50
 emerging coronavirus 15
 genetic 18
 immune-mediated 132
 management 43
 non-inflammatory 157
 pathogenesis 48
 pathogenicity 41
 pediatric-specific 153
 progression 12, 13
 rheumatic 15, 29
 vascular-related 159
Disorders 1, 12, 15, 16, 22, 29, 42, 45, 48, 51, 52, 121, 123, 125, 134, 136, 157
 allergic lung 136
 chronic corticosteroid-refractory 48
 cognitive 1, 16, 22
 immunology 121, 123
 inflammatory 2, 125, 134
 neurodegenerative 157
 neurological 16, 29
 pulmonary inflammatory 45
 rheumatic 12
Dizziness 122, 136
DNCB-induced atopic dermatitis 129, 130
Downstream signalling 57
Drugs 8, 16, 44, 47, 48, 52, 53, 54, 55, 56, 57, 76, 77, 78, 115, 152, 153, 154, 167, 168
 anti-allergic 77, 78, 115
 anti-cholinergic 53
 anti-diabetic 8
 anti-histamine 78
 anti-inflammatory 16, 55, 152
 immunosuppressive 55
 inflammatory 44
 thienopyridines 168
Drying mucus secretions 60
Dysfunction 16, 44, 57, 132
 cause airway 57
 neuronal cell 16
 vocal cord 44
Dyslipidemia 161
Dysmenorrhea 122
Dyspepsia 122, 154
- ## E
- Eczema 136
Edema 77, 124, 127, 165
 laryngeal 77, 165
Effects 17, 115, 124, 125, 126, 129, 132, 134, 139, 148, 150, 151, 153, 154, 156, 157, 169, 171
 ameliorative 129
 analgesic 148, 154
 antagonistic 115
 anti-analgesic 153
 anti-asthmatic 124, 139
 anti-hypertensive 156
 anti-inflammatory 17, 125, 134, 157
 antiplatelet 150, 169, 171
 antipyretic 148, 157
 anti-thrombin 151
 constituent's 126, 129, 132
 uricosuric 153
EGFR inhibitors 26
Endothelial progenitor cells (EPC) 13
Enzyme(s) 21, 58, 76, 111, 155
 histidine decarboxylase 76
 lipogenic 21
Eosinophil(s) 41, 43, 48, 55, 57, 60, 123, 124, 125, 127, 130, 132, 134, 136, 138, 165
 bloodstream 41
 chemotaxis 165
 granulocytes 43
 infiltrate 124
 infiltration 127
 targeted Treatment 57
Epithelial-mesenchymal transition (EMT) 19, 24, 25, 26

ERK inhibitors 14
Espiratory infections 45
Estrogen production 25
Expression of vascular endothelial growth factor 27, 60
Eye irritation 43

F

Factors 2, 5, 7, 10, 12, 24, 25, 27, 41, 45, 47, 49, 60, 134, 155, 156, 162
adipocyte-derived 2
anti-inflammatory 156
chemotactic 162
colony-stimulating 49
epidermal growth 27
inflammatory 5, 134
nuclear 12
pro-coagulant tissue 10
rheumatoid 12
thrombogenic 10
vascular endothelial growth 24, 27, 60
Fatty acid(s) (FAs) 8, 21, 23, 62, 157
free 8
synthase 21, 23
Fever 122, 147, 148
Fibers, elastin 10
Fibroblasts 50
Fibrogenesis 47
Fibronectin 26, 50
Fibrosis 50
basement membrane 50
Fluorophotometry 81
Food allergies 45, 140
Fractions 130, 131, 132, 133, 172
chromatographic 131

G

Gastric 77, 154
acid secretion 77
antioxidant defenses 154
ulcers 154
Gastrointestinal irritation 148
GATA binding protein 128
Gene expressions 9, 55, 125, 128
cytokine 125
reduced pro-inflammatory cytokines 125
Global Initiative for Asthma (GINA) 44, 52

Glucocorticoids 54, 55, 56
Gluconeogenesis 8
Glucose metabolism 16
neuronal 16
Glucuronic acid conjugation 153
Goblet cell hypertrophy 124
Granulocyte macrophage colony 46
stimulating factor (GMCSF) 46
Growth 18, 23, 25, 47, 48
synthesizing transforming 48
tumor 18, 25
Gut microbiota 6

H

HCC cells 19
HDL 11, 16
cholesterol 16
levels 11
Heart attack 160
Heart diseases 167, 168
ischemic 168
Heavy metal toxicity 46
Hemorrhage 154, 158
symptomatic intracerebral 158
Hepatic glucose production 8
Hepatocellular carcinoma 19
Hepatoprotective 122
HETE synthesis 156
High-density lipoprotein (HDL) 9, 135, 137
High-fat diet 6
Hip arthroplasty 159
Histamine 17, 47, 76, 77, 81, 82, 89, 91, 97, 108, 109, 115, 124, 125, 126, 127, 128
induced contraction 76, 82, 89, 91
reduced 124
spasmogens 124
synthesis 77
Histamine release 61, 79, 81, 82, 111, 113, 131, 133, 136, 162
inhibited 131
suppressing 82
Hyperlipidemia 9
Hyperplasia 50, 126, 139
Hypersecretion 62
Hypersensitivity reactions 166, 167, 173
Hypoalbuminemia 153
Hypotension 165

I

Illness, associated lower respiratory tract 138
Immune cell infiltration 4
Immune responses 15, 16, 27, 46, 47, 48, 123, 125, 126, 163, 157
 aggressive 15
 cytokines 123
 humoral 157
 innate 126
Immune system 6, 15, 17, 41, 43, 58, 77, 130, 132
Immunohistochemical analysis 19
Immunological 132
 deficiency syndromes 132
 disorders 132
Immunomodulatory 121, 132
 action 132
 properties 121
Immunomodulatory effects 124, 125, 126, 129, 130, 131, 140
 asthmatic mice's splenocytes.The 125
Induction of angiogenesis 22
Inflammation 1, 3, 6, 16, 18, 25, 41, 42, 43, 45, 46, 56, 57, 58, 60, 61
 fungal 42
 lung 125
Inflammatory 12, 47, 49, 58, 60, 129, 155, 165, 166
 cell permeation, reducing 60
 cells infiltration 129
 diseases, autoimmune 58
 mediators release 165
 response 12, 47, 49, 155, 166
Inhibiting histamine release 81
Inhibitor 4, 6, 7, 8, 55, 156
 angiotensin-converting enzyme 156
 insulin signaling 8
Insulin 4, 6, 7, 9
 sensitivity 4, 6, 9
 signaling 7
Intensity 18, 44, 133
 fluorescent 133
 itching 18
Interferon regulatory factors (IRF) 20
Ischemia 10, 158
 cerebral 158
Ischemic 157, 158, 160, 161, 170
 attack 161
 myocardium 157

strokes 158, 160
syndromes 170

J

JAK 5, 8, 9, 23, 28
 STAT signaling 5, 8
 inhibition 9
 pathways 9
 signaling pathways 23, 28
Jurkat leukemia cells 132

K

Kalonji 122
Kawasaki diseases and rheumatic fever 151
Kawasaki's syndrome 157

L

LABA continuation therapy 54
Leukocyte adhesion 157
Leukocytoclastic vasculitis 164
Leukotriene receptor antagonists 55
Lipolysis 6, 8
Lipopolysaccharide 128
Lipoxin production 159
Lipoxygenase 60
Low-density lipoprotein (LDL) 9, 10, 11, 22
Lower respiratory tract illness (LRTI) 138
Lung 23, 51
 adeno-carcinoma 23
 function test 51
Lymphangiogenesis 24, 27
Lymphocyte transformation test (LTT) 162, 163

M

Macrophage infiltration 10
Marine ecosystems 61
Matrix metalloproteinase 10, 24
Mechanisms 5, 11, 21, 26, 28, 45, 50, 135, 136, 164, 165, 167, 170, 173
 inflammatory 45
 of aspirin-induced hypersensitivity 164
 pathogenic 50
Mediators 4, 6, 7, 8, 11, 14, 17, 21, 22, 23, 24, 26, 27, 28, 52, 61, 170

anti-inflammatory 170
natural anti-inflammatory 61
proinflammatory 7
Medications, anti-cholinergic 41
Meningitis 166
Metabolic 2, 3, 5, 13
 diseases 2
 disorders 3, 5, 13
 syndrome 4, 5
Metabolites 77, 153
 active 77, 153
 saturations 153
Metastasis 18, 19, 23, 24, 25, 26, 27
 lung adenocarcinoma 26
 lymph node 19, 23
 tumor 19
Mitogen-activated protein kinase (MAPK) 3,
 4, 7, 8, 9, 21, 24
MMP 14, 22
 production 22
 release 14
Molecules 2, 4, 7, 9, 10, 12, 13, 17, 43, 58, 78,
 98, 103
 adhesion 9, 12
 pro-inflammatory 4
 signaling 10
Monoclonal antibody 57
Monocyte 14, 22, 48
 adhesion 14, 22
 and macrophages 48
Moringa oleifera 59, 61
mRNA expression 24, 27, 129
Multi-factorial event 162
Myeloma 24
Myocardial infarction (MI) 10, 147, 149, 155,
 156, 158, 159, 160, 171

N

Nasal 18, 22, 134, 136, 167
 mucosal congestion 134, 136
 obstruction 18, 22
 polyposis 167
Natural 58, 62, 130
 antioxidants 58
 killer (NK) 62, 130
Nervous system complications 16
Neurodegeneration 16
Neuroinflammation 22
Neurotransmission 76

Non-small-cell lung carcinoma (NSCLC) 25
Non-steroidal anti-inflammatory drugs
 (NSAIDs) 147, 152, 156, 162, 163

O

Obesity 8, 24
 associated adipocyte secretome (OAAS) 24
 related inflammation 8
Oils 58, 61, 122, 123, 124, 126, 127, 131, 132,
 133, 135, 136, 137, 138, 139, 140
 black seed 135
 essential 122
 sativa 123, 124, 126, 127, 136, 137, 138,
 139, 140
 volatile 58, 131, 132, 133
Ophthalmic lavage fluid (OLF) 129, 130
Osteoarthritis 1, 11, 13, 157
Osteoblasts 12
Osteoclastogenesis 13, 22
OVA-induced 123, 129
 bronchial asthma 123
 diarrhea 129
OVA-induced allergic 129
 conjunctivitis 129
 diarrhea 129
Ovarian carcinoma 24
OVA sensitization 124
Oxygenation 58

P

Pathophysiological events 6
Pathway 4, 6, 7, 8, 10, 18, 21, 24, 27, 29, 53,
 54, 136
 adrenergic nervous 54
 inflammatory 8, 18, 53
 inhibiting apoptotic 27
 insulin signaling 4, 6, 7, 8, 21
 lipoxigenase 136
Peptic ulcer 154
Pericarditis 151
Peripheral 131, 134, 159
 arterial disease 159
 blood mononuclear cells (PBMC) 131, 134
Phosphodiesterase inhibitors 55, 56
Polycystic ovary syndrome 5
Polymorphonuclear leukocytes 134, 137
Prognosis 13, 19

- Progression of neuroinflammation 22
Pro-inflammatory 4, 8, 17
 adipokines 8
 mediators 4, 17
Proliferating cell nuclear antigen (PCNA) 25
Prostate cancer 22, 157
Proteinases 10
Protein kinase 3, 4, 6, 7, 9, 24
 C (PKC) 6, 7, 24
 R (PKR) 4
Protein(s) 1, 2, 3, 11, 19, 24, 25, 28, 122, 152
 activating microsomal triglyceride transfer
 11
 cyclase-associated 1, 3, 7, 24
 heat shock 28
 phosphatase 24
Pseudo-Allergic/non-allergic Reactions 163
Pulmonary function tests (PFT) 137, 139
Pulmonary index (PI) 138
- R**
- Reactions 76, 79, 81, 86, 96, 99, 104, 106,
 108, 112, 114, 162, 164, 165
 antigen-antibody 81
 decarboxylation 76
 immunological 162
Reactive oxygen species (ROS) 4, 10, 12
Release 8, 10, 14, 17, 50, 58, 60, 77, 135, 150,
 155, 156
 cytokine 156
 leukotriene 60
Release cytokines 14
RELM proteins 2, 3
Reorganizing actin cytoskeleton 26
Resistin 8, 12
 downregulating 8
 synovial 12
Respiratory distress 122
Response, splenocyte 130
Rheumatic fever 151, 153
Rheumatoid arthritis (RA) 5, 11, 12, 13, 22,
 153
Rheumatoid factor (RF) 12, 13
- S**
- Salicylate toxicity 154
Sativa oil supplementation 137
Sativa preparations 138
Sativa proteins 131, 133
Sativa supplementation 134, 137
Secretion 8, 13, 20, 47, 49, 54, 56, 130, 131,
 165
 mucus gland 165
Sedative-hypnotic activity 97, 98, 99, 100,
 101, 102, 103, 105, 106, 107
Sepsis 15
Signaling pathways 3, 4, 14
Sinusitis 42, 45, 169
Skin rash 17
Smooth muscle 10, 47, 51, 59
 cells (SMCs) 10, 59
 hyperplasia 47, 51
 migration 47
Splenocyte(s) 128, 130, 131, 133, 134
 non-stimulated 131
 proliferation 130
Sputum eosinophils 41, 57
Steroids 53, 55, 56
Stevens-Johnson syndrome 164, 166
Stimulated synoviocytes 12
Stroke 10, 151, 155, 158, 159, 160
 lacunar 158
Structure-activity relationship (SAR) 101, 107
Subchondral sclerosis 14
Surgical revascularization 157
Symptoms 41, 42, 44, 51, 136, 137, 154, 160,
 162, 163, 165, 166, 169, 170
 nighttime 136, 137
 ophthalmic 136
Synovial fluid 11, 12, 13, 14, 22
Synoviocytes 12, 13
 resistin-stimulated 13
Synthesis 78, 79, 82, 91, 92, 95, 96, 100, 102,
 103, 104, 106, 108, 110, 114, 115, 154,
 170
 gastro-protective prostaglandins 154
 leukotriene 170
 of N-containing compounds 79
 ultrasound-assisted 110
Synthesis 94, 107
 of quinazoline derivatives 94
 of triazine derivatives 107
Synthesized compounds, antihistamine
 activity of 81, 83, 108, 111, 113, 114
Synthesizing 148
 acetylsalicylic acid 148
 salicylic acid 148

T

- Test 62, 81, 82, 137, 139, 162, 163, 166, 167
 - lymphocyte transformation 162, 163
 - oral provocation 167
 - provocative oral 167
 - pulmonary function 137, 139
 - reliable diagnostic 166
- Therapy 51, 62, 169, 170
 - antimicrobial 62
 - consistent 169
 - dual antiplatelet 170
 - steroid 51
- Thrombocytopenia 164
- Thrombosis 10, 151, 156, 159
 - coronary 151
- Thromboxane activity inhibition 154
- Tissues 20, 113
 - isolated guinea pig ileum 113
 - tumor-adjacent normal 20
- Toll-like receptors (TLRs) 4, 19, 128
- Trachea bronchomalacia 44
- Tracheal responsiveness (TR) 123, 124, 125, 126, 128
- Treatment of non-small-cell lung carcinoma 25
- Tumor 4, 7, 23, 24, 26, 124, 134
 - necrosis 4, 7, 24, 124, 134
 - progression 23, 26

V


- Vascular 24, 27, 60
 - cell adhesion molecule 24
 - endothelial growth factor (VEGF) 24, 27, 60
- Vitiligo area scoring index (VASI) 121
- VLDL overproduction 11

W

- White blood cell (WBC) 10, 77, 123, 128

Z

- Zingiber officinale* 61



PROF. DR. ATTA-UR-RAHMAN, FRS

Prof. Atta-ur-Rahman, Ph.D. in Organic Chemistry from Cambridge University (1968) has 1,232 international publications (45 international patents and 341 books). He received the following awards: Fellow Royal Society (FRS) London (2006), UNESCO Science Prize (1999), Honorary Life Fellow Kings College, Cambridge University (2007), Academician (Foreign Member) Chinese Academy of Sciences (2015), Highest Civil Award for Foreigners of China (Friendship Award, 2014), High Civil Award Austria ("Grosse Goldene Ehrenzeischen am Bande") (2007), Foreign Fellow Chinese Chemical Society (2013), Sc.D. Cambridge University (UK) (1987), TWAS (Italy) Prize (2009). He was the President of Network of Academies of Sciences of Islamic Countries (NASIC), Vice President TWAS (Italy), Foreign Fellow Korean Academy of Science & Technology, President Pakistan Academy of Sciences (2003-2006) and (2011 – 2014). He was the Federal Minister for Science and Technology of Pakistan (2000 – 2002), Federal Minister of Education (2002) and Chairman Higher Education Commission/Federal Minister (2002-2008), Coordinator General of COMSTECH (OIC Ministerial Committee) (1996-2012), and the Editor-in-Chief of Current Medicinal Chemistry.